Sunshine Biopharma Warrant Stock Price To Earning

SBFMW Stock

USD 0.16 0.07 30.43%

Sunshine Biopharma Warrant fundamentals help investors to digest information that contributes to Sunshine Biopharma's financial success or failures. It also enables traders to predict the movement of Sunshine Stock. The fundamental analysis module provides a way to measure Sunshine Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sunshine Biopharma stock.

Total Current Liabilities Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Sunshine Biopharma Warrant Company Price To Earning Analysis

Sunshine Biopharma's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Sunshine Price To Earning Driver Correlations

Understanding the fundamental principles of building solid financial models for Sunshine Biopharma is extremely important. It helps to project a fair market value of Sunshine Stock properly, considering its historical fundamentals such as Price To Earning. Since Sunshine Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sunshine Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sunshine Biopharma's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Net Receivables	Intangible Assets	Net Tangible Assets	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Good Will	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Investments
Total Assets		1.0	-0.99	-0.94	1.0	0.97	1.0	-0.28	0.35	0.98	0.73	0.76	-0.75	0.57	0.74	-0.73	1.0	0.88	-0.53	1.0	-0.73
Total Stockholder Equity	1.0		-1.0	-0.92	1.0	0.96	1.0	-0.29	0.31	0.99	0.73	0.75	-0.72	0.53	0.71	-0.75	1.0	0.87	-0.55	1.0	-0.75
Net Debt	-0.99	-1.0		0.92	-0.99	-0.96	-1.0	0.29	-0.36	-0.97	-0.7	-0.74	0.72	-0.55	-0.73	0.68	-1.0	-0.86	0.56	-0.99	0.68
Retained Earnings	-0.94	-0.92	0.92		-0.93	-0.97	-0.94	0.21	-0.43	-0.92	-0.81	-0.79	0.9	-0.74	-0.87	0.69	-0.93	-0.94	0.45	-0.95	0.69
Accounts Payable	1.0	1.0	-0.99	-0.93		0.97	1.0	-0.28	0.34	0.98	0.72	0.74	-0.73	0.55	0.72	-0.73	1.0	0.86	-0.54	1.0	-0.73
Total Liab	0.97	0.96	-0.96	-0.97	0.97		0.97	-0.25	0.51	0.93	0.7	0.75	-0.84	0.67	0.8	-0.65	0.97	0.89	-0.42	0.97	-0.65
Total Current Assets	1.0	1.0	-1.0	-0.94	1.0	0.97		-0.28	0.36	0.98	0.72	0.75	-0.75	0.58	0.74	-0.72	1.0	0.88	-0.53	1.0	-0.72
Common Stock	-0.28	-0.29	0.29	0.21	-0.28	-0.25	-0.28		-0.08	-0.27	-0.04	-0.36	0.34	-0.29	-0.33	0.2	-0.28	-0.34	0.29	-0.29	0.2
Short Term Debt	0.35	0.31	-0.36	-0.43	0.34	0.51	0.36	-0.08		0.19	-0.05	0.37	-0.49	0.48	0.54	0.24	0.39	0.39	-0.13	0.36	0.24
Net Receivables	0.98	0.99	-0.97	-0.92	0.98	0.93	0.98	-0.27	0.19		0.8	0.74	-0.72	0.53	0.69	-0.83	0.97	0.86	-0.53	0.98	-0.83
Intangible Assets	0.73	0.73	-0.7	-0.81	0.72	0.7	0.72	-0.04	-0.05	0.8		0.59	-0.69	0.62	0.7	-0.7	0.69	0.73	-0.33	0.73	-0.7
Net Tangible Assets	0.76	0.75	-0.74	-0.79	0.74	0.75	0.75	-0.36	0.37	0.74	0.59		-0.66	0.39	0.69	-0.55	0.75	0.86	-0.7	0.77	-0.55
Property Plant Equipment	-0.75	-0.72	0.72	0.9	-0.73	-0.84	-0.75	0.34	-0.49	-0.72	-0.69	-0.66		-0.91	-0.93	0.54	-0.73	-0.88	0.18	-0.77	0.54
Current Deferred Revenue	0.57	0.53	-0.55	-0.74	0.55	0.67	0.58	-0.29	0.48	0.53	0.62	0.39	-0.91		0.91	-0.3	0.55	0.7	-0.05	0.59	-0.3
Long Term Debt	0.74	0.71	-0.73	-0.87	0.72	0.8	0.74	-0.33	0.54	0.69	0.7	0.69	-0.93	0.91		-0.39	0.73	0.89	-0.32	0.76	-0.39
Good Will	-0.73	-0.75	0.68	0.69	-0.73	-0.65	-0.72	0.2	0.24	-0.83	-0.7	-0.55	0.54	-0.3	-0.39		-0.69	-0.7	0.39	-0.73	1.0
Net Invested Capital	1.0	1.0	-1.0	-0.93	1.0	0.97	1.0	-0.28	0.39	0.97	0.69	0.75	-0.73	0.55	0.73	-0.69		0.87	-0.54	1.0	-0.69
Short Long Term Debt	0.88	0.87	-0.86	-0.94	0.86	0.89	0.88	-0.34	0.39	0.86	0.73	0.86	-0.88	0.7	0.89	-0.7	0.87		-0.5	0.9	-0.7
Capital Stock	-0.53	-0.55	0.56	0.45	-0.54	-0.42	-0.53	0.29	-0.13	-0.53	-0.33	-0.7	0.18	-0.05	-0.32	0.39	-0.54	-0.5		-0.53	0.39
Net Working Capital	1.0	1.0	-0.99	-0.95	1.0	0.97	1.0	-0.29	0.36	0.98	0.73	0.77	-0.77	0.59	0.76	-0.73	1.0	0.9	-0.53		-0.73
Short Term Investments	-0.73	-0.75	0.68	0.69	-0.73	-0.65	-0.72	0.2	0.24	-0.83	-0.7	-0.55	0.54	-0.3	-0.39	1.0	-0.69	-0.7	0.39	-0.73

Click cells to compare fundamentals

Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Competition

Predict Sunshine Biopharma

Sunshine Retained Earnings

Retained Earnings

(60.71 Million)

Sunshine Biopharma reported Retained Earnings of (63.91 Million) in 2023

Based on the latest financial disclosure, Sunshine Biopharma Warrant has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and about the same as Health Care (which currently averages 0.0) industry. The price to earning for all United States stocks is 100.0% higher than that of the company.

Sunshine Price To Earning Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sunshine Biopharma's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sunshine Biopharma could also be used in its relative valuation, which is a method of valuing Sunshine Biopharma by comparing valuation metrics of similar companies.

Sunshine Biopharma is currently under evaluation in price to earning category among its peers.

Sunshine Fundamentals

	Return On Equity	-0.18
	Return On Asset	-0.11
	Profit Margin	(0.13) %
	Operating Margin	(0.13) %
	Number Of Shares Shorted	2.8 K
	Revenue	24.09 M
	Gross Profit	110.6 K
	EBITDA	(3.82 M)
	Net Income	(4.51 M)
	Cash And Equivalents	40.56 M
	Cash Per Share	1.80 X
	Total Debt	657.71 K
	Debt To Equity	8.98 %
	Current Ratio	85.09 X
	Book Value Per Share	12.52 X
	Cash Flow From Operations	(8.78 M)
	Earnings Per Share	(2.21) X
	Number Of Employees	44
	Beta	-1.04
	Total Asset	27.35 M
	Retained Earnings	(63.91 M)
	Working Capital	19.34 M
	Net Asset	27.35 M

About Sunshine Biopharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Sunshine Biopharma Warrant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sunshine Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sunshine Biopharma Warrant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

NVDA	NVIDIA
CRESY	Cresud SACIF y
GOOG	Alphabet Inc Class C

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC